Chemexpress(SH:688131) Xin Lang Cai Jing·2025-10-15 03:37Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical's stock has seen a significant increase, with a rise of 5.06% to 76.38 CNY per share, and a total market capitalization of 16.2 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds, as well as the production and technical improvement of active pharmaceutical ingredients and intermediates [1] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales contributing 63.42%, active pharmaceutical ingredients and intermediates 30.46%, technical services 5.55%, and other sources 0.57% [1] Group 2 - According to data, Guotai Fund holds Haoyuan Pharmaceutical as a significant investment, with the Guotai Innovation Medical Mixed Fund A (018159) holding 14,000 shares, accounting for 3.93% of the fund's net value, ranking as the seventh largest holding [2] - The Guotai Innovation Medical Mixed Fund A was established on April 18, 2023, with a latest scale of 12.614 million CNY, and has achieved a year-to-date return of 50.31%, ranking 623 out of 8161 in its category [2] - The fund manager, Qiu Xiaoxu, has a tenure of 3 years and 62 days, with the fund's total asset size at 871 million CNY, achieving a best return of 19.63% and a worst return of 0.83% during the tenure [3]